Linee guida AIAC 2010 per la gestione e il trattamento della - Stopfa

58
bolytic Survey Groups. Circulation 1998;97:
965-70.
327. Crenshaw BS, Ward SR, Granger CB,
Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation
in the setting of acute myocardial infarction:
the GUSTO-I experience. Global
Utilization of Streptokinase and TPA for Occluded
Coronary Arteries. J Am Coll Cardiol
1997;30:406-13.
328. Wong CK, White HD, Wilcox RG, et al.
New atrial fibrillation after acute myocardial
infarction independently predicts death: the
GUSTO-III experience. Am Heart J 2000;140:
878-85.
329. Pizzetti F, Turazza FM, Franzosi MG, et
al.; GISSI-3 Investigators. Incidence and
prognostic significance of atrial fibrillation in
acute myocardial infarction: the GISSI-3
data. Heart 2001;86:527-32.
330. Al-Khatib SM, Pieper KS, Lee KL, et al.
Atrial fibrillation and mortality among patients
with acute coronary syndromes without
ST-segment elevation: results from the PUR-
SUIT trial. Am J Cardiol 2001;88:A7,76-9.
331. Kinjo K, Sato H, Sato H, et al.; Osaka
Acute Coronary Insufficiency Study (OACIS)
Group. Prognostic significance of atrial fibrillation/atrial
flutter in patients with acute
myocardial infarction treated with percutaneous
coronary intervention. Am J Cardiol
2003;92:1150-4.
332. Forfar JC, Miller HC, Toft AD. Occult
thyrotoxicosis: a correctable cause of “idiopathic”
atrial fibrillation. Am J Cardiol 1979;
44:9-12.
333. Whittemore R, Hobbins JC, Engle MA.
Pregnancy and its outcome in women with
and without surgical treatment of congenital
heart disease. Am J Cardiol 1982;50:
641-51.
334. Bryg RJ, Gordon PR, Kudesia VS, Bhatia
RK. Effect of pregnancy on pressure gradient
in mitral stenosis. Am J Cardiol 1989;
63:384-6.
335. Bhanderi AK, Isher N. Cardiac arrhythmias
and pregnancies. In: Gleiche N,
ed. Principles and practice of medical therapy
in pregnancy. 3rd edition. Stamford, CT:
Appleton & Lange, 1998:975-87.
336. Page RL. Treatment of arrhythmias
during pregnancy. Am Heart J 1995;130:
871-6.
337. Chow T, Galvin J, McGovern B. Antiarrhythmic
drug therapy in pregnancy and
lactation. Am J Cardiol 1998;82(4A):58I-
62I.
338. Cox JL, Gardner MJ. Cardiovascular
drugs in pregnancy and lactation. In: Gleicher
N, Gall SA, Sibai BM, et al., eds. Principles
and practice of medical therapy in
pregnancy. Stamford, CT: Appleton & Lange,
1998:911-26.
339. Lownes HE, Ives TJ. Mexiletine use in
pregnancy and lactation. Am J Obstet Gynecol
1987;157:446-7.
340. Foster CJ, Love HG. Amiodarone in
pregnancy: case report and review of the literature.
Int J Cardiol 1988;20:307-16.
G ITAL CARDIOL | VOL 12 | SUPPL 1 AL N 1 2011
A RAVIELE ET AL
341. Wagner X, Jouglard J, Moulin M,
Miller AM, Petitjean J, Pisapia A. Coadministration
of flecainide acetate and sotalol
during pregnancy: lack of teratogenic effects,
passage across the placenta, and excretion
in human breast milk. Am Heart J
1990;119(3 Pt 1):700-2.
342. Ovadia M, Brito M, Hoyer GL, Marcus
FI. Human experience with amiodarone in
the embryonic period. Am J Cardiol 1994;
73:316-7.
343. Magee LA, Downar E, Sermer M, Boulton
BC, Allen LC, Koren G. Pregnancy outcome
after gestational exposure to amiodarone
in Canada. Am J Obstet Gynecol
1995;172(4 Pt 1):1307-11.
344. Leung CY, Brodsky MA. Cardiac arrhythmias
and pregnancy: diagnosis and
management of maternal and fetal disease.
In: Elkayam U, Gleicher N, eds. Cardiac
problems in pregnancy. 3rd edition. New
York, NY: Wiley-Liss, 1998:155-75.
345. Daoud EG, Marcovitz P, Knight BP, et
al. Short-term effect of atrial fibrillation on
atrial contractile function in humans. Circulation
1999;99:3024-7.
346. Nattel S, Li D. Ionic remodeling in the
heart: pathophysiological significance and
new therapeutic opportunities for atrial fibrillation.
Circ Res 2000;87:440-7.
347. Shi Y, Li D, Tardif JC, Nattel S. Enalapril
effects on atrial remodeling and atrial fibrillation
in experimental congestive heart failure.
Cardiovasc Res 2002;54:456-61.
348. Kumagai K, Nakashima H, Urata H,
Gondo N, Arakawa K, Saku K. Effects of angiotensin
II type 1 receptor antagonist on
electrical and structural remodeling in atrial
fibrillation. J Am Coll Cardiol 2003;41:2197-
204.
349. Li D, Shinagawa K, Pang L, et al. Effects
of angiotensin-converting enzyme inhibition
on the development of the atrial fibrillation
substrate in dogs with ventricular
tachypacing-induced congestive heart failure.
Circulation 2001;104:2608-14.
350. Nakashima H, Kumagai K, Urata H,
Gondo N, Ideishi M, Arakawa K. Angiotensin
II antagonist prevents electrical remodeling
in atrial fibrillation. Circulation
2000;101:2612-7.
351. Pedersen OD, Bagger H, Kober L, Torp-
Pedersen C. Trandolapril reduces the incidence
of atrial fibrillation after acute myocardial
infarction in patients with left
ventricular dysfunction. Circulation 1999;
100:376-80.
352. Bourassa MG, Gurne O, Bangdiwala
SI, et al. Natural history and patterns of current
practice in heart failure. The Studies of
Left Ventricular Dysfunction (SOLVD) Investigators.
J Am Coll Cardiol 1993;22(4 Suppl
A):14A-19A.
353. Wachtell K, Lehto M, Gerdts E, et al.
Angiotensin II receptor blockade reduces
new-onset atrial fibrillation and subsequent
stroke compared to atenolol: the Losartan
Intervention For End Point Reduction in Hy-
pertension (LIFE) study. J Am Coll Cardiol
2005;45:712-9.
354. Maggioni AP, Latini R, Carson PE, et
al.; Val-HeFT Investigators. Valsartan reduces
the incidence of atrial fibrillation in patients
with heart failure: results from the Valsartan
Heart Failure Trial (Val-HeFT). Am Heart J
2005;149:548-57.
355. Madrid AH, Bueno MG, Rebollo JM, et
al. Use of irbesartan to maintain sinus
rhythm in patients with long-lasting persistent
atrial fibrillation: a prospective and randomized
study. Circulation 2002;106:331-6.
356. Ueng KC, Tsai TP, Yu WC, et al. Use of
enalapril to facilitate sinus rhythm maintenance
after external cardioversion of longstanding
persistent atrial fibrillation. Results
of a prospective and controlled study. Eur
Heart J 2003;24:2090-8.
357. Yin Y, Dalal D, Liu Z, et al. Prospective
randomized study comparing amiodarone vs
amiodarone plus losartan vs amiodarone
plus perindopril for the prevention of atrial
fibrillation recurrence in patients with lone
paroxysmal atrial fibrillation. Eur Heart J
2006;27:1841-6.
358. Fogari R, Mugellini A, Destro M, et al.
Losartan and prevention of atrial fibrillation
recurrence in hypertensive patients. J Cardiovasc
Pharmacol 2006;47:46-50.
359. Tveit A, Grundvold I, Olufsen M, et al.
Candesartan in the prevention of relapsing
atrial fibrillation. Int J Cardiol 2007;120:85-91.
360. Disertori M, Latini R, Maggioni AP, et
al.; GISSI-AF Investigators. Rationale and design
of the GISSI-Atrial Fibrillation Trial: a
randomized, prospective, multicentre study
on the use of valsartan, an angiotensin II
AT1-receptor blocker, in the prevention of
atrial fibrillation recurrence. J Cardiovasc
Med 2006;7:29-38.
361. Disertori M, Latini R, Barlera S, et al.;
GISSI-AF Investigators. Valsartan for prevention
of recurrent atrial fibrillation N Engl
J Med 2009;360:1606-17.
362. Schneider MP, Hua TA, Bohm M,
Wachtell K, Kjeldsen SE, Schmieder RE. Prevention
of atrial fibrillation by renin-angiotensin
system inhibition: a meta-analysis.
J Am Coll Cardiol 2010;55:2299-307.
363. Dorian P, Singh BN. Upstream therapies
to prevent atrial fibrillation. Eur Heart J
Suppl 2008;10(Suppl H):H11-H31.
364. Kumagai K, Nakashima H, Saku K. The
HMG-CoA reductase inhibitor atorvastatin
prevents atrial fibrillation by inhibiting inflammation
in a canine sterile pericarditis
model. Cardiovasc Res 2004;62:105-11.
365. Shiroshita-Takeshita A, Brundel BJ,
Burstein B, et al. Effects of simvastatin on
the development of the atrial fibrillation
substrate in dogs with congestive heart failure.
Cardiovasc Res 2007;74:75-84.
366. Young-Xu Y, Jabbour S, Goldberg R, et
al. Usefulness of statin drugs in protecting
against atrial fibrillation in patients with
coronary artery disease. Am J Cardiol
2003;92:1379-83.